摘要
目的观察抗疏强骨合剂对骨质疏松患者血清中Ⅰ型前胶原氨基端延长肽(PINP)、β胶原降解产物(β-CTX)的影响及可能作用机理。方法134例原发性骨质疏松症患者随机分为治疗组和对照组,每组各67例。治疗组给予抗疏强骨合剂治疗,对照组给予碳酸钙D3片、阿仑膦酸钠片治疗,连续服用6个月后观察并分析各组治疗前后骨密度值、血清中PINP、β-CTX的表达情况以及临床有效率。结果(1)两种治疗方法均能改善患者腰椎及股骨颈部位的骨密度,但治疗组的效果更佳,更能提高患者的骨密度,与对照组比较,差异有统计学意义(P<0.05)。(2)两种治疗方法均能改善患者血清中PINP、β-CTX,但治疗组的效果更佳,与对照组比较,差异有统计学意义(P<0.05)。(3)治疗组临床有效率为89.55%(60/67),对照组临床有效率为77.61%(52/67),有统计学意义(P<0.05)。结论抗疏强骨合剂治疗原发性骨质疏松症疗效确切,能增加患者骨密度,促进骨形成,降低骨吸收,改善骨代谢,起到防治骨质疏松症的作用。
Objective To observe the effect of Kangshu Qianggu Mixture on the typeⅠprocollagen amino terminal prolongation peptide(PINP)andβ-collagen degradation product(β-CTX)in patients with osteoporosis and its possible mechanism.Methods A total of 134 patients with primary osteoporosis were randomly divided into treatment group and control group,with 67 cases in each group.The treatment group was treated with Kangshu Qianggu Mixture.The control group was treated with calcium carbonate D3 tablets and alendronate sodium tablets.After continuous administration for 6 months,the bone mineral density values,serum PINP andβ-CTX were observed and analyzed.Results(1)Both treatment methods can improve the bone density of the lumbar spine and the femoral neck,but the treatment group had better effect and can improve the bone density of the patients,which was significantly different from the control group(P<0.05).(2)Both treatments can improve PINP andβ-CTX in the serum of patients,but the effect of the treatment group was better,and it was significantly different from the control group(P<0.05).(3)The clinical effective rate was 89.55%(60/67)in the treatment group and 77.61%(52/67)in the control group,which was statistically significant(P<0.05).Conclusion Kangshu Qianggu Mixture is effective in the treatment of primary osteoporosis,which can increase bone density,promote bone formation,reduce bone resorption,improve bone metabolismand prevent osteoporosis.
作者
朱伟
董博
袁普卫
杨峰
欧国峰
王国柱
肖斌
陈瑞
郭杨
ZHU Wei;DONG Bo;YUAN Puwei;YANG Feng;OU Guofeng;WANG Guozhu;XIAO Bin;CHEN Rui;GUO Yang(Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000,Shaanxi,China;The Second Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang 712000,Shaanxi,China;Shaanxi University of Chinese Medicine,Xianyang 712046,Shaanxi,China)
出处
《辽宁中医杂志》
CAS
2020年第8期82-84,共3页
Liaoning Journal of Traditional Chinese Medicine
基金
国家自然科学基金(81574006)
陕西省卫生厅课题(2018A018)
陕西省重点科技创新团队项目(2013KJT-26)
全国名老中医药专家传承工作室建设项目(国中医药人教发[2018]134号)
关中李氏骨伤流派传承工作室项目(陕中医药发[2018]40号)
